AZD-1480

Product ID A9812

Cas No. 935666-88-9

Purity ≥99%

Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description
Product Info
Shipping and Storage
Downloads
References
Custom Order

Description

AZD-1480 is an inhibitor of JAK1/2 that exhibits antiviral, immunosuppressive, anti-metastatic, and anticancer chemotherapeutic activities. In vitro, AZD-1480 inhibits replication of hepatitis A virus. In animal models of experimental autoimmune encephalitis (EAE), AZD-1480 decreases disease severity by suppressing expression of inflammatory cytokines and minimizing antigen presentation and T cell expansion. In animal models of various cancers, this compound inhibits tumor growth. AZD-1480 is currently in clinical trials as a potential cancer treatment. In cellular and animal models of prostate cancer, this compound inhibits metastasis.

Product Info

Cas No.	935666-88-9
Purity	≥99%
Formula	C₁₄H₁₄ClFN₈
Formula Wt.	348.77
Synonym	AZD-1480
Solubility	DMSO 69 mg/mL warmed (197.83 mM) Water Insoluble Ethanol Insoluble
Appearance	White to off white powder

Shipping and Storage

Store Temp	-20°C
Ship Temp	Ambient

Downloads

MSDS	A9812 MSDS PDF
Info Sheet	A9812 Info Sheet PDF

References

Jiang X, Kanda T, Nakamoto S, et al. The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells. Biochem Biophys Res Commun. 2015 Feb 19. [Epub ahead of print]. PMID: 25704089.

Gritsina G, Xiao F, O'Brien SW, et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth. Mol Cancer Ther. 2015 Feb 2. [Epub ahead of print]. PMID: 25646015.

Suryani S, Bracken LS, Harvey RC, et al. Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2015 Feb;14(2):364-74. PMID: 25504635.

Houghton PJ, Kurmasheva RT, Lyalin D, et al. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Nov;61(11):1972-9. PMID: 25131802.

Gu L, Talati P, Vogiatzi P, et al. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther. 2014 May;13(5):1246-58. PMID: 24577942.

Liu Y, Holdbrooks AT, De Sarno P, et al. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol. 2014 Jan 1;192(1):59-72. PMID: 24323580.